Literature DB >> 9171936

Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells.

R S DiPaola1, W I Kuczynski, K Onodera, M Z Ratajczak, N Hijiya, J Moore, A M Gewirtz.   

Abstract

We sought to determine the functional significance of the c-kit receptor (Kit) in melanoma, breast carcinoma, and non-small cell lung cancer (NSCLC). To explore these issues, we first screened cell lines of each type for c-kit mRNA expression using a reverse-transcription polymerase chain reaction. We found that WM-39 melanoma cells, HTB-22 breast carcinoma cells, and A549 NSCLC cells all expressed c-kit mRNA. Of interest, all of these cells expressed the c-kit ligand, Steel factor (SF). We then assessed the functional significance of c-kit and SF expression by disrupting the gene's expression with antisense (AS) oligodeoxynucleotides (ODN) targeted to c-kit mRNA codons 1-6 and SF mRNA codons 2-7, respectively. Nonhybridizing sequences [sense (5) and scrambled (SCR)] were also employed as controls. WM-39, HTB-22, and A549 cells were exposed to ODN (approximately 25 microM) for 5-7 days. Downregulation of c-kit and SF mRNA, and c-kit protein was demonstrated in cells treated with AS ODN. Effects on viable cell growth were demonstrated by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) or 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 -sulfophenyl)- 2H-tetrazolium (MTS) assay. In fact, c-kit antisense ODN inhibited the viable cell growth of A549 cells 66% and 79% compared to sense and untreated controls (P = .0003; P < .0001). Additionally, WM-39 cell growth was inhibited 48% and 21% (P < .0001, P < .03) and HTB-22 cell growth was inhibited 50% (P < .001) compared to sense and untreated controls. Viable cell growth was also significantly inhibited by SF AS ODN compared to S and SCR controls in all cell lines. These results demonstrate that WM-39, HTB-22, and A549 NSCLC cells all express the c-kit and SF protooncogenes and suggest that the encoded receptor and ligand are important for cell growth. By finding the presence, and functional importance, of both the receptor and ligand in these cells, this study suggests the existence of an autocrine loop growth mechanism worthy of further study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171936

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  16 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  Antiplasmodial activity of alkaloid extracts from Pavetta crassipes (K. Schum) and Acanthospermum hispidum (DC), two plants used in traditional medicine in Burkina Faso.

Authors:  S Sanon; N Azas; M Gasquet; E Ollivier; V Mahiou; N Barro; N Cuzin-Ouattara; A S Traore; F Esposito; G Balansard; P Timon-David
Journal:  Parasitol Res       Date:  2003-04-04       Impact factor: 2.289

3.  Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies.

Authors:  Nermeen S Youssef; Azza M Said
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  Poorly differentiated carcinoma of the rectum with aberrant immunophenotype: a case report.

Authors:  A Giannopoulos; I Papaconstantinou; P Alexandrou; A Petrou; A Papalambros; E Felekouras; E Papalambros
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

5.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Authors:  Helen K Chew; William E Barlow; Kathy Albain; Danika Lew; Allen Gown; Daniel F Hayes; Julie Gralow; Gabriel N Hortobagyi; Robert Livingston
Journal:  Clin Breast Cancer       Date:  2008-12       Impact factor: 3.225

6.  The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium.

Authors:  Chang Dae Ko; Jee Soo Kim; Byung Gyun Ko; Byung Ho Son; Hee Joon Kang; Ho Sung Yoon; Eun Yoon Cho; Gyungyub Gong; Sei Hyun Ahn
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 7.  Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib.

Authors:  Janice N Cormier; Shreyaskumar R Patel; Peter W T Pisters
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

8.  Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells.

Authors:  Chong-Zhi Wang; Han H Aung; Bin Zhang; Shi Sun; Xiao-Li Li; Hui He; Jing-Tian Xie; Tong-Chuan He; Wei Du; Chun-Su Yuan
Journal:  Anticancer Res       Date:  2008 Sep-Oct       Impact factor: 2.480

9.  Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

Authors:  M Cristofanilli; P Morandi; S Krishnamurthy; J M Reuben; B-N Lee; D Francis; D J Booser; M C Green; B K Arun; L Pusztai; A Lopez; R Islam; V Valero; G N Hortobagyi
Journal:  Ann Oncol       Date:  2008-05-29       Impact factor: 32.976

10.  Prognostic value of CD117 in cancer: a meta-analysis.

Authors:  Fuyou Zhao; Yuqing Chen; Qiong Wu; Zian Wang; Jie Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.